FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040376994> ?p ?o ?g. }

• W2040376994 endingPage "168" @default.
• W2040376994 startingPage "163" @default.
• W2040376994 abstract "Goblet cell hyperplasia (GCH) and mucus hypersecretion in the airway is recognized as an important contributor to morbidity and mortality in asthma and COPD. Verapamil is a calcium channel blocker that binds to the alpha-subunit of L-type calcium channels and inhibits the mucin gene via the calmodulin and CaM kinase pathway. The objective of this study was to determine the in vivo effect of verapamil on GCH and eosinophilic inflammation in sensitized mice. Male BALB/c mice were sensitized to ovalbumin using the standard method. Two groups of animals were received verapamil via an intramuscular injection: 1-low dose (0.5 mg/kg/day for two weeks), 2-high dose (1.5 mg/kg/day for two weeks). Serum and bronchoalveolar lavage fluid (BALF) was collected and analyzed for inflammatory cells, interferon-γ and IL-4. The left lung was sent for histopathological evaluation, especially for periodic acid-Schiff (PAS), to identify goblet cells in the epithelium. The degree of inflammatory cell infiltration, including eosinophils, mucus plugging, and smooth muscle thickness of the airways were classified on a semi quantitative scale. Inflammatory cell infiltration in peribronchial and perivascular areas was observed in all sensitized groups. Eosinophils percentage in the BALF significantly decreased in verapamil-treated mice compared with sensitized mice (from 19.8% in asthmatic to 5.4% for low dose and 4.4% for high dose). The ratio of airway goblet cells per epithelial cells were significantly lower in verapamil-treated mice versus sensitized mice (1.57 ± 1.30% for low dose; 1.50 ± 0.93% for high dose versus 12.93 ± 7.55%, P < 0.05, respectively). Mucus production of goblet cells decreased significantly in verapamil-treated mice versus sensitized mice (mean score was 1.45 ± 0.30 for low dose; 0.81 ± 1.00 for high dose versus 2.85 ± 0.86 in the sensitized control group, P < 0.05, respectively). The concentration of serum and BALF-IFN-γ in verapamil-treated mice markedly increased by the verapamil treatment when compared to sensitized mice (15.1 ± 0.43 versus 4.7 ± 0.96, P < 0.05 and 91.8 ± 47.7 versus 14.8 ± 4.6, P < 0.01, respectively). Verapamil is a useful drug with therapeutic targeting on GCH and a potential way to limit mucous production and improve bronchial inflammation." @default.
• W2040376994 created "2016-06-24" @default.
• W2040376994 creator A5038610887 @default.
• W2040376994 creator A5069666328 @default.
• W2040376994 creator A5073903620 @default.
• W2040376994 creator A5075869479 @default.
• W2040376994 creator A5084457940 @default.
• W2040376994 creator A5085385594 @default.
• W2040376994 creator A5090583832 @default.
• W2040376994 date "2012-04-01" @default.
• W2040376994 modified "2023-09-23" @default.
• W2040376994 title "Effect of verapamil on bronchial goblet cells of asthma: An experimental study on sensitized animals" @default.
• W2040376994 cites W1509483174 @default.
• W2040376994 cites W1918954179 @default.
• W2040376994 cites W1920101996 @default.
• W2040376994 cites W1964510097 @default.
• W2040376994 cites W1981720530 @default.
• W2040376994 cites W1993412130 @default.
• W2040376994 cites W2005473631 @default.
• W2040376994 cites W2013657285 @default.
• W2040376994 cites W2015471725 @default.
• W2040376994 cites W2021497228 @default.
• W2040376994 cites W2036322357 @default.
• W2040376994 cites W2044945022 @default.
• W2040376994 cites W2045121129 @default.
• W2040376994 cites W2046172305 @default.
• W2040376994 cites W2046661997 @default.
• W2040376994 cites W2049216745 @default.
• W2040376994 cites W2059897878 @default.
• W2040376994 cites W2072376737 @default.
• W2040376994 cites W2087310183 @default.
• W2040376994 cites W2094898219 @default.
• W2040376994 cites W2106034623 @default.
• W2040376994 cites W2121431809 @default.
• W2040376994 cites W2128052381 @default.
• W2040376994 cites W2131666175 @default.
• W2040376994 cites W2135132799 @default.
• W2040376994 cites W2135418193 @default.
• W2040376994 cites W2147684493 @default.
• W2040376994 cites W2159862329 @default.
• W2040376994 cites W2161362125 @default.
• W2040376994 cites W2164092307 @default.
• W2040376994 doi "https://doi.org/10.1016/j.pupt.2011.11.001" @default.
• W2040376994 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22133887" @default.
• W2040376994 hasPublicationYear "2012" @default.
• W2040376994 type Work @default.
• W2040376994 sameAs 2040376994 @default.
• W2040376994 citedByCount "26" @default.
• W2040376994 countsByYear W20403769942013 @default.
• W2040376994 countsByYear W20403769942014 @default.
• W2040376994 countsByYear W20403769942015 @default.
• W2040376994 countsByYear W20403769942016 @default.
• W2040376994 countsByYear W20403769942017 @default.
• W2040376994 countsByYear W20403769942018 @default.
• W2040376994 countsByYear W20403769942019 @default.
• W2040376994 countsByYear W20403769942020 @default.
• W2040376994 countsByYear W20403769942021 @default.
• W2040376994 countsByYear W20403769942022 @default.
• W2040376994 countsByYear W20403769942023 @default.
• W2040376994 crossrefType "journal-article" @default.
• W2040376994 hasAuthorship W2040376994A5038610887 @default.
• W2040376994 hasAuthorship W2040376994A5069666328 @default.
• W2040376994 hasAuthorship W2040376994A5073903620 @default.
• W2040376994 hasAuthorship W2040376994A5075869479 @default.
• W2040376994 hasAuthorship W2040376994A5084457940 @default.
• W2040376994 hasAuthorship W2040376994A5085385594 @default.
• W2040376994 hasAuthorship W2040376994A5090583832 @default.
• W2040376994 hasConcept C121332964 @default.
• W2040376994 hasConcept C126322002 @default.
• W2040376994 hasConcept C142724271 @default.
• W2040376994 hasConcept C153400128 @default.
• W2040376994 hasConcept C179264091 @default.
• W2040376994 hasConcept C18903297 @default.
• W2040376994 hasConcept C203014093 @default.
• W2040376994 hasConcept C2775941134 @default.
• W2040376994 hasConcept C2776042228 @default.
• W2040376994 hasConcept C2776914184 @default.
• W2040376994 hasConcept C2776946954 @default.
• W2040376994 hasConcept C2777022698 @default.
• W2040376994 hasConcept C2777037409 @default.
• W2040376994 hasConcept C2777300124 @default.
• W2040376994 hasConcept C2777312293 @default.
• W2040376994 hasConcept C2777714996 @default.
• W2040376994 hasConcept C2777961210 @default.
• W2040376994 hasConcept C519063684 @default.
• W2040376994 hasConcept C529295009 @default.
• W2040376994 hasConcept C71924100 @default.
• W2040376994 hasConcept C86803240 @default.
• W2040376994 hasConcept C8891405 @default.
• W2040376994 hasConcept C97355855 @default.
• W2040376994 hasConcept C98274493 @default.
• W2040376994 hasConceptScore W2040376994C121332964 @default.
• W2040376994 hasConceptScore W2040376994C126322002 @default.
• W2040376994 hasConceptScore W2040376994C142724271 @default.
• W2040376994 hasConceptScore W2040376994C153400128 @default.
• W2040376994 hasConceptScore W2040376994C179264091 @default.
• W2040376994 hasConceptScore W2040376994C18903297 @default.
• W2040376994 hasConceptScore W2040376994C203014093 @default.

• next